EP2416756A2 - Compositions pharmaceutiques stables à forte biodisponibilité - Google Patents

Compositions pharmaceutiques stables à forte biodisponibilité

Info

Publication number
EP2416756A2
EP2416756A2 EP10731618A EP10731618A EP2416756A2 EP 2416756 A2 EP2416756 A2 EP 2416756A2 EP 10731618 A EP10731618 A EP 10731618A EP 10731618 A EP10731618 A EP 10731618A EP 2416756 A2 EP2416756 A2 EP 2416756A2
Authority
EP
European Patent Office
Prior art keywords
strontium
treatment
pharmaceutical composition
sodium
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP10731618A
Other languages
German (de)
English (en)
Inventor
Mahmut Bilgic
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bilgic Mahmut
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of EP2416756A2 publication Critical patent/EP2416756A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches

Definitions

  • the present invention relates to pharmaceutical compositions comprising an active agent alone or in combination with another active agent which is used for the treatment and/or prophylaxis of diseases and conditions associated with abnormal bone resorption and/or effective as a supplement.
  • the present invention provides a pharmaceutical composition which is used for the treatment and/or prophylaxis of diseases and conditions associated with abnormal bone resorption and/or effective as a supplement
  • Strontium is an earth-alkali metal that has high chemical reactivity. It was first discovered by Thomas Charles Hope in 1798. Strontium ranelate (Formula I) was first described in United States Patent application 5128367 (European Patent number 0415850 is also a member of the patent family). The process for the preparation of strontium ranelate and its use for the treatment of bone disorder, especially for osteoporosis, are described in this patent.
  • Strontium is an element which has a high affinity to the bone tissue. Due to its high chemical and physical similarity to calcium, it can be used instead of calcium and can show the same activity. Its anti-osteoporotic effect is suggested to demonstrate itself with a dual mechanism of bone production improvement and bone resorption reduction.
  • 89 Sr is a radiopharmaceutical used for bone pain secondary to metastatic bone cancer. The strontium acts like calcium and is preferentially incorporated into bone at sites of increased osteogenesis. This localization focuses the radiation exposure on the cancerous lesion.
  • 90 Sr is used as radiotherapy in cancer treatment due to its beta emission and long half-life characteristics.
  • Strontium ranelate being one of the strontium compounds is effective in bone growth, increasing bone density and lessening bone fractures and the use of granule form of strontium ranelate for oral suspension is approved in Europe.
  • Vitamin D is a group of fat-soluble prohormones, the two major forms of which are vitamin D 2 (or ergocalciferol) and vitamin D 3 (or cholecalciferol). There are also D 1 , D 4 and D 5 forms. The term vitamin D also refers to these metabolites and other analogues of these substances. Vitamin D 3 is a vitamin D form with the chemical name (3 ⁇ ,5Z,7E)-9,10-secocholesta- 5,7,10(19)-trien-3-ol (Formula II).
  • Vitamin D 3 is the form of vitamin D that is synthesized naturally in the body. It is synthesized in the skin from 7-dehydrocholesterol, a sterol present in the mammalian skin, under the action of ultraviolet light. Vitamin D 3 can be obtained partially from animal products. Vitamin D 3 is hydroxylated in the liver and kidney, and becomes calcitriol (1,25- dihydroxyvitamin D 3 ).
  • Calcitriol plays an important role in the maintenance of the calcium balance and the parathyroid hormone regulation. It stimulates the renal reabsorption of calcium, and increases the intestinal absorption of calcium and phosphorus and their mobilization from the bone to the plasma. It is believed that the absorption of calcium in the intestines is achieved by the calcitriol by binding to specific receptors in the cytoplasm of intestinal mucosa cells. Then calcium is absorbed by formation of a calcium binding protein. When calcium and phosphorus levels of plasma reach saturation, mineralization occurs in the bone. Vitamin D affects the absorption of strontium in the same way as it affects calcium absorption. Hence, Vitamin D can be added to a strontium composition to be used for the treatment and/or prophylaxis of diseases and conditions associated with abnormal bone resorption and/or as a supplement.
  • the present invention relates to pharmaceutical compositions which are effective for the treatment and/or prophylaxis of diseases and conditions associated with abnormal bone resorption and/or as a supplement.
  • the mentioned compositions comprise a strontium compound alone or in combination with vitamin D.
  • the object of the invention is to provide a composition comprising the active agent or agents in a pharmaceutically acceptable, non-toxic and therapeutically effective amount according to the invention and the formulation of these active agent/agents to achieve this desired effect.
  • European Patent No. 1534305 describes the use of strontium malonate with a solubility of 1- 100 g/1 at room temperature, for prevention and/or treatment of various bone conditions.
  • European Patent No. 1534305 European Application No. 1745791 describes the use of some strontium salts also with a solubility of 1-100 g/1 at room temperature, for prevention and/or treatment of various bone conditions. It has been indicated in these patents that these novel salts encounter no solubility problems.
  • vitamin D The tendency of vitamin D to degrade when exposed to heat, light, air, moisture, oxidizing agents or an acidic environment raises the problem of stability with the formulations comprising vitamin D. This situation raises the necessity of using an auxiliary agent to ensure the stability of vitamin D in the tablet.
  • the present invention provides stable, highly soluble and hence bioavailable pharmaceutical compositions comprising a strontium compound alone or in combination with Vitamin D to formulate the composition for maintaining the "desired effect".
  • the present invention relates to the use of pharmaceutical compositions comprising a strontium compound alone or in combination with vitamin D, in the manufacture of a medicament used for the treatment and/or prophylaxis of diseases and conditions associated with abnormal bone resorption and/or as a supplement in a liquid dosage form or a solid dosage form which transforms into liquid form just before administration.
  • the present invention is directed to obtain stable, highly soluble and hence bioavailable pharmaceutical compositions comprising a strontium compound alone or in combination with Vitamin D to formulate the composition for maintaining the "desired effect".
  • Strontium ranelate a strontium salt effective in the treatment of osteoporosis, released to market in Europe in the form of granules for oral suspension.
  • the present invention is directed to solution formulations which are preferred instead of suspension formulations in order to increase the bioavailability of pharmaceutical compositions comprising a strontium compound.
  • These previously mentioned solution compositions might be either in a liquid dosage form or in a solid dosage form which transforms into liquid phase just before administration.
  • the pharmaceutical compositions of the invention preferably in the effervescent tablet form highly improve the bioavailability because they are already administered in dissolved form and already provide the use of active agent in high amounts.
  • the pharmaceutical formulation composition of the present invention are characterized in that they provide formulations comprising a high dose of a strontium compound in effervescent form to improve solubility, thus bioavailability; instead of restrictive and complicated methods, which require both time and capital, such as use of a solubility enhancing agent, preparation of novel strontium salts with improved solubility, addition of at least two strontium salts to enhance bioavailability and enhancement of the release characteristics of tablet dosage form.
  • Strontium carbonate can be used alone or in combination with other strontium compounds because of the fact that the effervescent formulations of the invention are effective as a carbondioxide source and improve bioavailability by increasing active agent dose.
  • the pharmaceutical compositions preferably in tablet dosage form may also comprise a small amount of sweetener and/or flavoring agent as taste promoter.
  • compositions of the present invention may be formulated comprising a strontium compound alone or also a strontium compound in combination with vitamin D as an active agent.
  • a strontium compound alone or also a strontium compound in combination with vitamin D as an active agent.
  • the stability problem arises due to vitamin D.
  • Pharmaceutical compositions of the invention in effervescent form comprise disintegrants which cause tablets to disintegrate, in other words to dissolve, thus increasing the bioavailability and also providing the stability of the composition.
  • Pharmaceutical compositions of the invention preferably in effervescent form can also comprise at least one stabilizing agent.
  • compositions comprising a strontium compound alone or in combination with vitamin D, in liquid or solid dosage form which transforms into liquid form just before administration, preferably in effervescent tablet form, and optionally comprising an additive selected from the group consisting of diluents, binders, disintegrants, lubricants, glidants, surfactants, stabilizing agents, sweeteners and flavoring agents, have improved solubility, bioavailability and stability characteristics and the pharmaceutical compositions are used for the treatment and/or prophylaxis of diseases and conditions associated with abnormal bone resorption and/or effective as a supplement.
  • the term "used for the treatment and/or prophylaxis of diseases and conditions associated with abnormal bone resorption and/or as a supplement” used herein refers to the use of treatment of osteoporosis; treatment of osteoporosis by reducing the risk of post-menopausal bone fractures of the spine and hip bones in women; treatment of osteoporosis for reducing the risk of bone fractures in men; treatment of idiopathic osteoporosis; treatment of various disease related osteoporosis; treatment of steroid and glucocorticoid related osteoporosis; treatment of osteoarthritis; treatment of osteopetrosis; treatment of osteopenia; treatment of osteomalacia; treatment of osteodystrophy; treatment of osteogenesis imperfecta; treatment of osteochondrodysplasia; treatment of Sudeck's atrophy, treatment of rheumatoid arthritis, treatment of Paget's disease, treatment of Bechterew's disease, treatment of Behcet's disease, treatment of periodon
  • the pharmaceutical compositions contain strontium compound in the range of 0.1-75% by weight and an amount of vitamin D in the range of 100-100000 IU to achieve the desired therapeutic effect.
  • strontium compound indicates strontium adipate, strontium alendronate, strontium alginate, strontium acetate, strontium ascorbate, strontium aspartate, strontium benzenesulfonate, strontium benzoate, strontium borate, strontium bromate, strontium bromide, strontium butanoate, strontium butirate, strontium decanoate, strontium ethanesulfonate, strontium etidronate, strontium fluoride, strontium formate, strontium phosphate, strontium fumarate, strontium glyconate, strontium glycocholate, strontium glutamate, strontium glutarate, strontium hexanoate,
  • the pharmaceutically acceptable diluents can be selected from the group of lactose, microcrystalline cellulose, starch, pregelatinized starch, modified starch, calcium phosphate (dibasic and/or tribasic), calcium sulphate trihydrate, calcium sulphate dihydrate, calcium carbonate, caolin, lactitol, powdered cellulose, dextrose, dextrates, dextrin, sucrose, maltose, fructose, mannitol, sorbitol and xylitol.
  • the diluent is present in the formulation preferably in a range of 0-85% by weight, more preferably in a range of 0.1-75% by weight.
  • the pharmaceutically acceptable binders can be selected from the group of starch (e.g. potato starch, cornstarch or wheat starch), sucrose, glucose, dextrose, lactose, sugars like maltodexrin, natural and synthetic gums (e.g. acacia tree), gelatin, cellulose derivatives (e.g. microcrystalline cellulose, HPC, HEC, HPMC, carboxymethylcellulose, methylcellulose, ethylcellulose), polyethylene glycol (PEG), waxes, calcium carbonate, calcium phosphate, alcohols (e.g. sorbitol, xylitol and mannitol) and water.
  • the binder is present in the formulation preferably in a range of 0-10% by weight, more preferably in a range of 0.1-5% by weight.
  • the pharmaceutically acceptable disintegrants can be selected from the group of starch (e.g. potato starch, cornstarch or wheat starch), sodium starch glycolate, pregelatinized starch, cellulose derivatives (such as croscarmellose sodium or microcrystalline cellulose), polyvinylpyrrolidone (PVP), crospovidone, alginic acid, sodium alginate, clays (such as Xanthan gum or Veegum), ion-exchange resins and effervescent systems (alkali or alkaline earth metal carbonates (e.g. sodium carbonate, sodium hydrogen carbonate, potassium carbonate, potassium hydrogen carbonate, calcium carbonate, and strontium carbonate), water-soluble organic acids and salts (e.g.
  • starch e.g. potato starch, cornstarch or wheat starch
  • sodium starch glycolate e.g. potato starch, cornstarch or wheat starch
  • pregelatinized starch e.g. potato starch, cornstarch or wheat starch
  • the disintegrant is present in the formulation preferably in a range of 0-85% by weight, more preferably in a range of 0.1-75% by weight.
  • the pharmaceutically acceptable lubricants can be selected from the group of metallic stearates (e.g. magnesium stearate, calcium stearate, aluminum stearate), fatty acid esters (e.g. sodium stearyl fumarate), fatty acids (e.g. stearic acid), fatty alcohols, glyceryl behenate, mineral oils, paraffins, hydrogenated vegetable oils, leucine, polyethylene glycols (PEG), metallic lauryl sulfates (e.g. sodium lauryl sulfate, magnesium lauryl sulfate), sodium chloride, sodium benzoate and sodium acetate.
  • metallic stearates e.g. magnesium stearate, calcium stearate, aluminum stearate
  • fatty acid esters e.g. sodium stearyl fumarate
  • fatty acids e.g. stearic acid
  • fatty alcohols e.g. glyceryl behenate
  • mineral oils e
  • the lubricant is present in the formulation preferably in a range of 0-10% by weight, more preferably in a range of 0.1-5% by weight.
  • the pharmaceutically acceptable glidants can be selected from the group of silicon dioxide, magnesium trisilicate, powdered cellulose, starch, talc, tribasic calcium phosphate, metallic stearates, calcium silicate and metallic lauryl sulfate.
  • the weight % of the glidant in the formulation is lower than 1%.
  • the pharmaceutically acceptable surfactants can be selected from the group of polyoxyethylene sorbitan fatty acid (polysorbates), sodium lauryl sulphate, sodium stearyl fumarate, polyoxyethylene castor oil derivatives, docusate sodium, quatenary ammonia compounds, amino acids like L-leucine, sugar esters of fatty acids and glycerides of fatty acids.
  • the lubricant is present in the formulation preferably in a range of 0-10% by weight, more preferably in a range of 0.1-5% by weight.
  • the stabilizing agent(s) and antioxidants can be selected from the group of chelating agents, alkalizing agents and photoprotectors.
  • the stabilizing agent is present in the formulation preferably in a range of 0-10% by weight, more preferably in a range of 0.1-5% by weight.
  • the antioxidants can be selected from the group of butylated hydroxyanisole (BHA), sodium ascorbate, butylated hydroxytoluene (BHT), sodium sulphite, gallates (e.g. propyl gallate), tocopherol, citric acid, malic acid, ascorbic acid, acetylcysteine, fumaric acid, lecithin, ascorbyl palmitate, ethylenediamine tetraacetate.
  • BHA butylated hydroxyanisole
  • BHT butylated hydroxytoluene
  • gallates e.g. propyl gallate
  • tocopherol citric acid, malic acid, ascorbic acid, acetylcysteine, fumaric acid, lecithin, ascorbyl palmitate, ethylenediamine tetraacetate.
  • the chelating agents can be selected from the group of disodium EDTA, edetic acid, citric acid, sodium citrate, potassium citrate and combinations.
  • the alkalizing agents can be selected from the group of alkali metal salts like sodium hydrogen carbonate, sodium dihydroxide, sodium silicate, disodium hydrogen orthophosphate, sodium aluminate; earth alkali salts like calcium carbonate, calcium hydroxide, dibasic calcium phosphate, tribasic calcium phosphate, calcium sulphate, calcium acetate, calcium gluconate, calcium glycerophosphate, magnesium carbonate, magnesium hydroxide, magnesium sulphate, magnesium acetate, magnesium silicate, magnesium aluminate; primary, secondary and tertiary amines, cyclic amines, N 5 N'- dibenzylethylenediamine, diethanolamin, ethylenediamine, meglumine, monosodium glutamate, polacrilin sodium and sodium alginate.
  • alkali metal salts like sodium hydrogen carbonate, sodium dihydroxide, sodium silicate, disodium hydrogen orthophosphate, sodium aluminate
  • earth alkali salts
  • the photoprotectors can be selected from the group of titanium oxide, iron oxide and zinc.
  • the pharmaceutically acceptable sweeteners can be selected from the group of sucralose, sucrose, fructose, glucose, galactose, xylose, dextrose, levulose, lactose, maltose, maltodextrin, mannitol, maltitol, maltol, sorbitol, xylitol, erythriol, lactitol, isomalt, corn syrup, saccarine, saccarine salts, acesulfame potassium, aspartam, D-tryptophan, monoammonium glycyrrhizinate, neohesperidin dihydrochalcone, thaumatin, neotame, alitame, stevioside and cyclamate.
  • the sweeteners are present in the formulation preferably in a range of 0-10% by weight, more preferably in a range of 0.1-5% by weight.
  • the pharmaceutically acceptable flavoring agents can be selected from the following group; natural aroma oils (peppermint oil, partridge currant oil, clove bud oil, parsley oil, eucalyptus oil, lemon oil, orange oil, etc.), menthol, menthane, anethole, methyl salicylate, eucalyptol, cinnamon, 1 -methyl acetate, sage, eugenol, oxanone, ⁇ -irisone, marjoram, lemon, orange, propenyl guaethol acetyl, vanillin, thymol, linalool, cinnamaldehyde glycerol acetal, N- substituted-p-menthane-3-carboxamide, 3,1-methoxy propane- 1,2-diol.
  • the flavoring agent is present in the formulation preferably in a range of 0-10% by weight, more preferably in a range of 0.1 -5% by weight.
  • solubility modulators In addition to these, solubility modulators, electrolytes, colorants and coatings can be used as other pharmaceutical excipients in the formulation.
  • Example 1 Example 2.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne des compositions pharmaceutiques comprenant un agent actif seul ou combiné à un autre agent actif, utilisé pour le traitement et/ou la prophylaxie de maladies et d'affections associées à une résorption osseuse anormale et/ou efficace sous forme de complément.
EP10731618A 2009-04-10 2010-04-09 Compositions pharmaceutiques stables à forte biodisponibilité Withdrawn EP2416756A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR200902817 2009-04-10
PCT/TR2010/000081 WO2010117346A2 (fr) 2009-04-10 2010-04-09 Compositions pharmaceutiques stables à forte biodisponibilité

Publications (1)

Publication Number Publication Date
EP2416756A2 true EP2416756A2 (fr) 2012-02-15

Family

ID=42711940

Family Applications (1)

Application Number Title Priority Date Filing Date
EP10731618A Withdrawn EP2416756A2 (fr) 2009-04-10 2010-04-09 Compositions pharmaceutiques stables à forte biodisponibilité

Country Status (2)

Country Link
EP (1) EP2416756A2 (fr)
WO (1) WO2010117346A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11219594B2 (en) 2015-12-12 2022-01-11 Steerlife India Private Limited Effervescent compositions of metformin and processes for preparation thereof

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR201110525A2 (tr) * 2011-01-06 2012-07-23 Bi̇lgi̇ç Mahmut Kemik hastalıklarının tedavisinde kullanılmak üzere suda çözünebilir farmasötik bileşimler.
EP2530068A1 (fr) 2011-05-31 2012-12-05 Lacer, S.A. Nouveaux sels de strontium, leur synthèse et leur utilisation dans le traitement de l'ostéoporose
PT106978A (pt) * 2013-05-31 2014-12-02 Tecnimede Sociedade Tecnico Medicinal S A Composição sólida oral contendo ácido ibandrónico e vitamina d
TWI651103B (zh) 2013-12-13 2019-02-21 萊特醫技股份有限公司 多相骨移植替代材料
WO2016042372A1 (fr) 2014-09-17 2016-03-24 Steer Engineering Private Limited Composition effervescente et son procédé de fabrication
WO2017120480A1 (fr) * 2016-01-07 2017-07-13 Purecircle Usa Inc. Glycosides de stéviol hautement solubles

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3888976A (en) * 1972-09-21 1975-06-10 William P Mlkvy Zinc and strontium ion containing effervescent mouthwash tablet
FR2651497B1 (fr) 1989-09-01 1991-10-25 Adir Nouveaux sels de metaux bivalents de l'acide n, n-di (carboxymethyl)amino-2 cyano-3 carboxymethyl-4 carboxy-5 thiophene, leur procede de preparation et les compositions pharmaceutiques les renfermant.
PT1534305E (pt) 2003-05-07 2007-02-28 Osteologix As Tratamento de afecções cartilagineas / osseas com sais de estroncio hidrosoluveis
US20060216358A1 (en) * 2003-05-07 2006-09-28 Christian Hansen Controlled release composition containing a strontium salt
ITFI20030194A1 (it) * 2003-07-17 2005-01-18 Menarini Int Operations Lu Sa Composizione farmaceutiche effervescenti contenenti
DK1768748T4 (da) * 2004-06-25 2019-06-11 Mokwalo Spf S A Sammensætninger omfattende strontium og vitamin D og anvendelser deraf
EP1899314A2 (fr) 2005-07-06 2008-03-19 Osteologix A/S Procedes de synthese a rendement eleve destines a la production de sels organiques de strontium
US20090012163A1 (en) * 2007-07-02 2009-01-08 Gaffar Maria C Compositions containing Mg/Zn/F-CaP plus inhibitors of pro-inflammatory cytokines (alpha ketoalkanoic acid compound) for osteoporosis prevention, therapy and treatment of bone diseases
AT9980U1 (de) * 2007-09-13 2008-07-15 Tritthart Technology & Consult Zusammensetzung enthaltend ein vitamin d und vorzugsweise einen mineralstoff

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2010117346A2 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11219594B2 (en) 2015-12-12 2022-01-11 Steerlife India Private Limited Effervescent compositions of metformin and processes for preparation thereof

Also Published As

Publication number Publication date
WO2010117346A3 (fr) 2010-12-02
WO2010117346A2 (fr) 2010-10-14

Similar Documents

Publication Publication Date Title
AU2010249227B2 (en) Controlled release composition containing a strontium salt
EP2496222B1 (fr) Compositions pharmaceutiques comprenant du calcium et de la vitamine d
WO2010117346A2 (fr) Compositions pharmaceutiques stables à forte biodisponibilité
JP5036765B2 (ja) 水溶性ストロンチウム塩を用いる軟骨／骨症状の治療
KR930010621B1 (ko) 안정성이 개량된 활성형 비타민 d3류 고형제제
US8324191B2 (en) Combined calcium, magnesium and vitamin D supplements
US20050026871A1 (en) Method of increasing bioavailability of alendronate or other bis-phosphonate by predose administration of vitamin D derivative
WO2011152810A1 (fr) Formulations comprenant du calcium, de la vitamine d et de la vitamine k pour traiter l'ostéoporose
CN1148341A (zh) 口服阿来屈酯液体制剂
JP2011241221A (ja) ビタミンｄ誘導体の前用量投与によってアレンドロネート等のビスフォスフォネートの生体利用効率を高める方法
JP2011148814A (ja) 軟骨および／または骨の症状の予防および／または治療のためのストロンチウムを用いる併用治療
RU2533230C2 (ru) Фармацевтические композиции, содержащие производные бисфосфоната и высокие дозы холекальциферола
EP2393478B1 (fr) Compositions pharmaceutiques à l'odeur et au goût masqués hautement biodisponibles
JP6374879B2 (ja) 骨粗しょう症治療用の安定な医薬組成物
KR20000076042A (ko) 비타민 디3 및 트리칼슘 포스페이트를 함유하는 안정한 고체 제제
US20130164342A1 (en) Formulations for osteoporosis
EP2393516B1 (fr) Compositions pharmaceutiques stables, à goût et odeur masqués comprenant de la n-acétylcystéine et de la vitamine c
WO2009087652A2 (fr) Compositions pharmaceutiques de calcitriol et de suppléments minéraux
WO2012093971A2 (fr) Compositions effervescentes contenant de l'amlodipine
EP2661258B1 (fr) Formulation améliorée à base de risédronate
WO2008075930A1 (fr) Compositions de risedronate et vitamine d3
WO2012093976A1 (fr) Composition comportant de l'ibandronate, au moins 50 % d'un agent de charge et un agent édulcorant
TW201828936A (zh) 穩定且適口之維生素c及鋅組合物口含錠

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20111102

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: BILGIC, MAHMUT

RIN1 Information on inventor provided before grant (corrected)

Inventor name: BILGIC, MAHMUT

17Q First examination report despatched

Effective date: 20140606

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20141101